Status:

COMPLETED

A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

Lead Sponsor:

Novartis

Collaborating Sponsors:

Genentech, Inc.

Tanox

Conditions:

Asthma

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair

Eligibility Criteria

Inclusion

  • Male and female adult patients, body weight between 40-150 kg aged 18-65 years (inclusive)
  • Patients diagnosed with asthma with Forced Expiratory Volume (FEV1) ≥65% of the predicted normal value for the patient
  • Positive skin prick test to a specific allergen
  • Patients had to demonstrate a Provocative Dose 20% FEV1 decline (PD20) response to an aeroallergen in the graded allergen bronchoprovocation testing (ABP) at screening

Exclusion

  • Current active smokers
  • Patients who have been hospitalized or had emergency treatment for an asthma attack in the 12 months prior to study start
  • History of bleeding disorders
  • History of drug allergy
  • Pregnant women or nursing mothers
  • Females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception (surgical contraception or double barrier methods (to be continued for at least two months following last dose) are acceptable).
  • Sexually active males who have not been sterilized and are not using a condom
  • History of immunocompromise, including a positive HIV
  • A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
  • History of drug or alcohol abuse within 12 months of study start
  • Other protocol-defined inclusion/exclusion criteria may apply

Key Trial Info

Start Date :

February 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2009

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00624832

Start Date

February 1 2008

End Date

January 1 2009

Last Update

April 19 2011

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Novartis Investigator Site

Berlin, Germany

2

Novartis Investigator Site

Frankfurt, Germany

3

Novartis Investigator Site

Munich, Germany

4

Novartis Investigator Site

Groningen, Netherlands